Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.
鈉-葡萄糖共轉運蛋白 2 抑制劑與 2 型糖尿病老年患者新發癡呆風險及全因死亡率的關聯:基於 TriNetX 美國合作網絡的回顧性隊列研究。
Diabetes Obes Metab 2024-09-09
Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials.
鈉-葡萄糖共轉運蛋白 2 抑制劑對心血管和腦血管疾病的影響:一項受控臨床試驗的 meta-analysis。
Front Endocrinol (Lausanne) 2024-09-09
Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.
與使用鈉-葡萄糖共轉運蛋白-2抑制劑相比,使用胰高血糖素樣肽-1受體激動劑和噻唑烷二酮在代謝功能障礙相關脂肪肝疾病患者中肝臟事件的風險。
Gut 2024-09-06
SGLT2 Inhibitor and Urinary Tract Infection in Men at Risk for Voiding Dysfunction: A VigiBase Analysis.
SGLT2 抑制劑與有排尿功能障礙風險男性的尿路感染:VigiBase 分析。
Urol Pract 2024-09-06
Investigation of cardiorenal outcomes and incidence of genitourinary tract infection after combined SGLT2 inhibitor and ACEI/ARB use in patients with chronic kidney disease stages 3-5: A real-world retrospective cohort study in Taiwan.
慢性腎病第3-5期患者使用聯合 SGLT2 抑制劑與 ACEI/ARB 後心腎結果及泌尿道感染發生率的調查:台灣的一項真實世界回顧性隊列研究。
Int J Med Sci 2024-09-06